---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021971"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:53:38.411225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track

## Summary
- Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.
- Net loss $6.2M ($0.15/sh) vs $5.6M ($1.74/sh) in Q1 2023; R&D expense up 35.6% to $3.7M.
- Phase 2b trial for VYN201 in nonsegmental vitiligo to enroll ~160 subjects in 1%,2%,3% gel vs vehicle; first dose expected Q2 2024.
- IND cleared for oral BET inhibitor VYN202; Phase 1a SAD/MAD starting Q2 2024 with top-line data H2 2024.
- Top-line Phase 2b data expected mid-2025; Phase 1b trials in psoriasis and RA planned for H2 2025 if Phase 1a successful.

## SEC filing metadata
- accession: 0001628280-24-021971
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/0001628280-24-021971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/mnlo-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021971
- JSON: https://secwatch.observer/filing/0001628280-24-021971.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021971.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.
  - Period: the quarter ended March 31, 2024
  - Revenue: $0.1 million
  - Net income: $6.2 million
  - EPS: $0.15
  - Result: reported results
  source text: financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/0001628280-24-021971-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.